tretazicar has been researched along with mitomycin in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sugget, N; Walton, MI; Workman, P | 1 |
Riley, RJ; Workman, P | 1 |
Melo, T; Misra, V; Rauth, AM | 1 |
Ackerley, DF; Barak, Y; Contag, CH; Lynch, SV; Matin, A; Thorne, SH | 1 |
Celli, CM; Jaiswal, AK; Knox, R; Tran, N | 1 |
Boddy, AV; Jamieson, D; Knox, RJ; Tung, AT | 1 |
1 review(s) available for tretazicar and mitomycin
Article | Year |
---|---|
DT-diaphorase and cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Dihydrolipoamide Dehydrogenase; Drug Design; Enzyme Induction; Gene Expression Regulation, Enzymologic; Humans; Indolequinones; Indoles; Mitomycin; Neoplasms; Precancerous Conditions; Tirapazamine; Triazines | 1992 |
5 other study(ies) available for tretazicar and mitomycin
Article | Year |
---|---|
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma 256, Walker; Cell Hypoxia; Colonic Neoplasms; Humans; In Vitro Techniques; Indolequinones; Indoles; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Prodrugs; Rats; Tirapazamine; Triazines | 1992 |
Bioreductive therapies: an overview of drugs and their mechanisms of action.
Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; DNA, Neoplasm; Forecasting; Humans; Indolequinones; Indoles; Misonidazole; Mitomycin; Nitrofurans; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1998 |
New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.
Topics: Antineoplastic Agents; Aziridines; Drug Delivery Systems; Escherichia coli Proteins; Evolution, Molecular; HeLa Cells; Humans; Mitomycin; Neoplasms; Oxidoreductases; Prodrugs; Salmonella typhimurium; Sequence Analysis, Protein | 2006 |
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzopyrenes; Biotransformation; Cell Survival; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Cross-Linking Reagents; DNA, Complementary; Dose-Response Relationship, Drug; Hydroquinones; Indolequinones; Keratinocytes; Mice; Mice, Knockout; Mitomycin; Mitomycins; Quinone Reductases; Quinones; Transfection; Vitamin K 3 | 2006 |
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
Topics: Alkylating Agents; Animals; Aziridines; Catalysis; Cell Line; Comet Assay; Electron Transport; Humans; Mitomycin; NAD; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Quercetin; Quinone Reductases; Recombinant Proteins; Transfection | 2006 |